PUMA BIOTECHNOLOGY: Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to Treat HER2-Positive Metastatic Breast Cancer | FDA Health News
Puma Biotechnology
Here's Why Puma Biotechnology Inc (NASDAQ:PBYI) Is Running Up - Market Exclusive
Puma Biotechnology
Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe | Business Wire
HCW starts Puma Biotechnology at buy; PT $15 | BioTuesdays
PUMA BIOTECHNOLOGY: FDA Approves Labeling Supplement for Puma Biotechnology's NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer | FDA Health News
$51.61 Million in Sales Expected for Puma Biotechnology, Inc. (NASDAQ:PBYI) This Quarter - Opera News
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | FiercePharma
PharmaShots - Incisive news in 3 shots on Twitter: "Puma Biotechnology Reports Results of Neratinib (PB272) in P-III NALA Trial for 3L HER2-Positive Metastatic Breast Cancer https://t.co/KKTvnp68jJ… https://t.co/sWLJCNJzQV"
Former Puma Biotech executive gets U.S. prison term for insider trading | Reuters
Why Puma Biotechnology, Inc. Stock Crashed 37% in March | Fox Business
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
Puma Biotechnology: Risky Investment (NASDAQ:PBYI) | Seeking Alpha
Will Puma Biotechnology Break Out of Its Rut in 2020? | The Motley Fool
European Patent Board Rules in Favour of Puma Biotechnology - IP News Shots
Puma Biotechnology
Puma Biotechnology
Puma Biotechnology, Inc. 2020 Q2 - Results - Earnings Call Presentation (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology - Crunchbase Company Profile & Funding
Puma Biotechnology
Is Puma Biotechnology a Buy? | The Motley Fool
Federal Jury Awards Puma Biotechnology Investors Damages in Securities Class-Action Verdict | Los Angeles Business Journal
Sonsuz analoji Paketlemek puma pharmaceuticals - alpproduksiyon.com
Puma Shares Soar 81% Over 2 Days | Los Angeles Business Journal
Puma Biotechnology (PBYI) Presents At Barclays Global Healthcare Virtual Conference (NASDAQ:PBYI) | Seeking Alpha
Puma Biotechnology Crashed After Lagging More Bullish Views For Breast Cancer Drug Nerlynx | Stock News & Stock Market Analysis - IBD
